Skip to main content
Premium Trial:

Request an Annual Quote

Meridian's Group B Streptococcus Test Approved for Sale in Australia

NEW YORK (GenomeWeb News) – Meridian Bioscience's wholly owned subsidiary Bioline announced today that its illumigene Group B Streptococcus test has received regulatory approval for commercialization in Australia.

Clearance from the Therapeutic Goods Administration follows similar action in the US by the Food and Drug Administration.

The test is based on loop-mediated isothermal DNA amplification technology and detects Streptococcus agalactiae from enriched cultures from vaginal swabs. Results can be achieved in less than an hour, Meridian said, adding that GBS remains a major prenatal pathogen and is associated with significant morbidity and mortality in infants.

"illumigene GBS is a key addition to the illumigene platform given the importance of early detection of GBS to prevent serious disease in infants," Richard Eberly, COO of Meridian, said in a statement. "This new test begins the expansion of the illumigene platform and provides a molecular technology that is affordable, simple, and quick."

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.